Physician profile
Abigail James
NPI 1285755538
$57,807.26
in general payments reported to CMS, 2019-2025
33 companies · $9,819 in 2025
The $9,819 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $9,256 · 2022: $13K · 2023: $14K · 2024: $11K · 2025: $9,819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $8,375 · Consulting Fee: $3,472 · Travel and Lodging: $2,441 · Education: $483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,307.00 |
| Food and Beverage | $8,374.92 |
| Consulting Fee | $3,472.00 |
| Travel and Lodging | $2,441.36 |
| Education | $482.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18,082.02 | 2021-2025 | Otezla, Otezla |
| Genzyme Corporation | $15,489.31 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $15,174.41 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $1,378.11 | 2021-2025 | |
| Leo Pharma INC. | $1,121.02 | 2023-2025 | Adbry |
| Janssen Biotech, INC. | $948.64 | 2021-2025 | Tremfya |
| Abbvie INC. | $866.97 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $840.11 | 2022-2025 | Ilumya |
| Incyte Corporation | $537.26 | 2021-2025 | Opzelura |
| Ucb, INC. | $508.62 | 2021-2025 | Bimzelx |
| Pfizer INC. | $478.46 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $336.92 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $320.40 | 2022-2025 | Sotyktu |
| Organogenesis INC. | $297.68 | 2022-2023 | Puraply |
| Almirall LLC | $253.80 | 2022-2025 | Seysara |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $209.84 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $178.39 | 2021-2025 | Nemluvio, Aklief |
| Dermavant Sciences, INC. | $148.86 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $102.34 | 2023-2025 | Jublia, Cabtreo, Arazlo |
| Convatec INC. | $67.10 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $61.68 | 2025 | Dupixent |
| Organon LLC | $59.29 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.69 | 2022-2025 | Spevigo |
| Botanix Sb INC | $51.22 | 2025 | Sofdra |
| Biofrontera INC. | $48.75 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Epi Health, LLC | $44.45 | 2022 | |
| Mallinckrodt Hospital Products INC. | $38.85 | 2025 | Acthar |
| Allergan, INC. | $24.85 | 2022 | |
| Medimetriks Pharmaceuticals, INC. | $19.57 | 2023 | Neo-Synalar |
| Journey Medical Corporation | $16.40 | 2022 | |
| Mayne Pharma Commercial LLC | $16.35 | 2025 | |
| Sanofi-Aventis U.S. LLC | $14.50 | 2021 | |
| Verrica Pharmaceuticals INC. | $13.40 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.